Treatmentexperimental

Thymosin Alpha-1 Therapy

An immune-modulating peptide marketed by clinics for immune support, resilience, chronic infection recovery and 'immune anti-aging'.

An immune-modulating peptide marketed by clinics for immune support, resilience, chronic infection recovery and 'immune anti-aging'. Sold as a subcutaneous injectable course.

Evidence

experimental

It is approved abroad as an immune adjuvant for specific conditions (e.g. hepatitis), but there is no adequate human evidence for the marketed immune-longevity or general anti-aging claim.

Regulatory notes

European Union
Not EMA/AEMPS-authorised; no approved marketed human product for longevity use in Spain/EU.
United States
Not FDA-approved for human use; sold only as a compounded/research substance and no member of the thymosin family is FDA-approved as of 2026.
United Arab Emirates
No DHA/DoH registration; not authorised as a licensed prescription medicine.
United Kingdom
Not MHRA-licensed for human use; lawful only in unlicensed/special contexts, not as a wellness product.

General information, not medical or legal advice. See our disclaimer.

Also known as

thymosin alpha 1, Ta1, Tα1, Zadaxin, thymalfasin

Where to find it

40 clinics in the directory offer thymosin alpha-1 therapy. Prices shown are the cheapest for this treatment where published; always confirm with the venue.

Back to glossary